OncoMyx Therapeutics

OncoMyx Therapeutics is advancing oncolytic immunotherapies with the goal of achieving the greatest therapeutic benefit for more cancer patients. Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have the potential to be a safe and effective complement to immunotherapies. OncoMyx has assembled the top immuno-oncology team to develop oncolytic immunotherapies based on the myxoma virus platform to orchestrate an immune response with the goal of better treating a wide range of cancers. The company’s myxoma virus platform is poised to be a best-in-class oncolytic virus approach and was developed based on breakthrough research from Dr. Grant McFadden’s lab that was exclusively licensed from Arizona State University. For more info, visit www.oncomyx.com.